Keystone Capital Partners, a New York-based investment platform specializing in the biotech, real estate and consumer products sectors, provided foundational seed capital to Stella Diagnostics, a molecular diagnostics-based organization focused on improving patient management strategies for those living with severe esophageal disease.
The amount of the deal was not disclosed. As part of the transaction, Daniel Wainstein, Managing Partner and Chief Operating Officer of Keystone, will join Stella’s board of directors.
Led by Joe Abdo, co-founder and CEO, Stella Diagnostics is a molecular diagnostics-based organization focused on improving patient management strategies for the over 67 million people living with severe esophageal disease. The company’s proprietary technology offers physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing, or turning cancerous.